Alzheimer's Disease - Pipeline Review, H2 2014

Alzheimer's Disease - Pipeline Review, H2 2014 is a new market research publication announced by Reportstack. This report provides an overview of the Alzheimer's Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

AB Science AbbVie Inc. AC Immune SA Acadia Pharmaceuticals Inc. Accera, Inc. Acelot, Inc. Acumen Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc. Addex Therapeutics Ltd Advanced Cell Technology, Inc. Affichem AFFiRiS AG Alector LLC ALSP, Inc. AlzeCure Discovery AB Alzhyme Pty Ltd Alzinova AB AlzProtect SAS Amarantus Bioscience Holdings, Inc. Amgen Inc. Anavex Life Sciences Corp. Angita B.V. Apodemus AB Araclon Biotech, S.L. Archer Pharmaceuticals, Inc. ArmaGen Technologies, Inc. Artery Therapeutics, Inc. Astellas Pharma Inc. AstraZeneca PLC Ausio Pharmaceuticals, LLC Avergen Ltd Avineuro Pharmaceuticals, Inc. Axerion Therapeutics, Inc. Axon Neuroscience SE Axxam SpA Azevan Pharmaceuticals, Inc. BioArctic Neuroscience AB biOasis Technologies Inc. Biogen Idec Inc. Biomar Microbial Technologies Bionature E.A. Ltd. Bionure Farma, S.L. Biotie Therapies Corp. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company BSIM2 CalAsia Pharmaceuticals, Inc. Cardax Pharmaceuticals, Inc. Celon Pharma Sp. z o.o. CHA Bio & Diostech Co., Ltd. Chase Pharmaceuticals Corporation Clera Inc. Cognition Therapeutics, Inc. Cognosci, Inc. CoLucid Pharmaceuticals, Inc. CoMentis, Inc. Cortica Neurosciences, Inc. Critical Outcome Technologies Inc. CrystalGenomics, Inc. D-Pharm Ltd. Daewoong Pharmaceutical Co., Ltd. Delenex Therapeutics AG DermaXon, LLC Domain Therapeutics SA Echo Pharmaceuticals B.V. Eisai Co., Ltd. Eli Lilly and Company EncephRx, Inc. EndoCeutics, Inc. Epigen Biosciences, Inc. Eucalyptus Ltd. Euroscreen S.A. Evotec AG F. Hoffmann-La Roche Ltd. FORUM Pharmaceuticals Inc. Galantos Pharma GmbH Genentech, Inc. Genervon Biopharmaceuticals, LLC GlaxoSmithKline plc GliaCure Inc. Grifols, S.A. H. Lundbeck A/S High Point Pharmaceuticals, LLC Humanetics Corporation Ichor Medical Systems, Inc. Icure Pharmaceutical Inc. IMMD Inc. Immunome Inc. ImStar Therapeutics Inc. Inovio Pharmaceuticals, Inc. Intellect Neurosciences, Inc. Intra-Cellular Therapies, Inc. Io Therapeutics, Inc. Iproteos S.L. Janssen Pharmaceuticals, Inc. Jeil Pharmaceutical Co., Ltd. Johnson & Johnson K-Stemcell Co., Ltd. Kareus Therapeutics, SA KineMed, Inc. Kyowa Hakko Kirin Co., Ltd. Laila Pharmaceuticals Pvt. Ltd. Lead Discovery Center GmbH Les Laboratoires Servier SAS Lipopharma Therapeutics SL Living Cell Technologies Limited Lupin Limited ManRos Therapeutics MedDay Medestea Research & Production S.p.A. MediPost Co., Ltd. Medisyn Technologies, Inc. Merck & Co., Inc. Merz Pharma GmbH & Co. KgaA Metabolic Solutions Development Company, LLC Mezzion Pharma Co. Ltd. Mithridion, Inc. NAL Pharmaceuticals Ltd. Nanomerics Ltd Nanotherapeutics, Inc. NasVax Ltd. Naurex, Inc. Neuralstem, Inc. Neurim Pharmaceuticals Ltd Neurodyn Inc. NeuroGenetic Pharmaceuticals, Inc. Neurokine Pharmaceuticals Inc. Neuron Biopharma SA NeuroNascent, Inc. Neuronax SAS NeurOp, Inc NeuroPhage Pharmaceuticals, Inc. Neurotez, Inc. nLife Therapeutics, S.L. Northern Light Pharmaceuticals AB Novartis AG NsGene A/S Nymox Pharmaceutical Corporation Octapharma AG Oligomerix, inc. Oryzon Genomics S.A. OXIS International, Inc. (Inactive) P2D Bioscience Pain Therapeutics, Inc. PALUMED S.A. Panacea Pharmaceuticals, Inc. PeptiDream Inc. Peptron, Inc. Pfizer Inc. PharmatrophiX, Inc. Pharnext SAS Phenomenome Discoveries, Inc. PhysioGenix, Inc. Plexxikon Inc. Prana Biotechnology Limited Probiodrug AG Proteome Sciences Plc ProteoTech, Inc. Prothena Corporation plc QR Pharma, Inc. RAPID Pharmaceuticals AG ReGenX Biosciences, LLC reMYND Resverlogix Corp. Reviva Pharmaceuticals Inc. Richter Gedeon Nyrt. Sage Therapeutics Saneron CCEL Therapeutics, Inc. Sangamo BioSciences, Inc. Sanofi Selvita SA Serometrix, LLC Siena Biotech S.p.A. SignPath Pharma Inc Simcere Pharmaceutical Group SK Biopharmaceuticals Co., Ltd. SK Chemicals Co., Ltd. SOM Innovation Biotech SL Spectrum Pharmaceuticals, Inc. Stelic Institute & Co. StemCells, Inc. Stemedica Cell Technologies, Inc. Sumitomo Dainippon Pharma Co., Ltd. Summit Corporation plc Suven Life Sciences Ltd. TauRx Therapeutics Ltd. Tautatis Incorporated TechnoPhage SA Teikoku Pharma USA, Inc. tesa Labtec GmbH Tetra Discovery Partners LLC The International Biotechnology Center (IBC) “Generium” Toyama Chemical Co., Ltd. Transition Therapeutics Inc. TransTech Pharma, Inc. Treventis Corporation Trophos SA TyrNovo Ltd. Umecrine Cognition AB United Biomedical, Inc. Upsher-Smith Laboratories, Inc. Valens Therapeutics, Inc. Varinel, Inc. Virobay Inc. Vitae Pharmaceuticals, Inc. VivaCell Biotechnology Espana S.L. Vivus, Inc. Vybion, Inc. Xenetic Biosciences plc Zenobia Therapeutics, Inc.To view the table of contents and know more details please visit Alzheimer's Disease - Pipeline Review, H2 2014